46 completed, 9 recruiting, 5 unknown, 2 not yet recruiting. 64 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 64 | Completed 46, Recruiting 9, Unknown 5, Not yet recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Unknown 2 |
Follow Chickenpox: new trials by email Literature Review of Chickenpox trials Research Report on Chickenpox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps | Phase 3 | Not yet recruiting | GlaxoSmithKline | 1860 | 2026-08-11 | 2026-08-03 |
| SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years NBP608 (Mid Potency), NBP608 (Low Potency), Varivax® - Varicella (Chickenpox) | Phase 3 | Recruiting | SK Bioscience Co., Ltd. | 780 | 2026-07-04 | 2026-09-15 |
| Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above ABO1108, Placebo - Varicella-zoster Virus | Phase 3 | Recruiting | Suzhou Abogen Biosciences Co., Ltd. | 18000 | 2026-06-27 | 2026-09-14 |
| Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Varicella Vaccine - Varicella (Chickenpox), Varicella Immunisation | Phase 3 | Not yet recruiting | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 300 | 2026-06-15 | 2026-06-12 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years MG1111 (Barycela inj.), VARIVAX™ - Varicella (Chickenpox), Chickenpox Vaccine | Phase 3 | Recruiting | GC Biopharma Corp | 474 | 2026-03-17 | 2026-04-17 |
| Second Dose of Varicella Vaccine in Healthy Children PROVARIX - Varicella (Chickenpox), Varicella Immunisation | Phase 3 | Recruiting | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 300 | 2026-01-28 | 2026-03-16 |
| A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 600 | 2025-05-15 | 2026-05-29 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 911 | 2025-04-17 | 2026-05-29 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3 - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 1840 | 2025-01-10 | 2026-05-29 |
| A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 750 | 2024-11-26 | 2026-05-29 |
| Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines Varicella Vaccine, Varivax - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 642 | 2024-02-29 | 2025-01-27 |
| A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age Investigational live attenuated varicella vaccine (lot 1), Investigational live attenuated varicella vaccine (lot 2), Investigational live attenuated varicella vaccine (lot 3) - Varicella | Phase 3 | Unknown | China National Biotec Group Company Limited | 1200 | 2023-04-27 | 2023-06-18 |
| A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine Investigational live attenuated varicella vaccine, Placebo of live attenuated varicella vaccine - Varicella | Phase 3 | Unknown | China National Biotec Group Company Limited | 12440 | 2022-12-26 | 2023-06-18 |
| Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd., Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd - Varicella | Phase 3 | Completed | Shanghai Institute Of Biological Products | 2480 | 2022-02-13 | 2023-12-29 |
| Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd, Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd, Placebo - Varicella | Phase 3 | Unknown | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2400 | 2021-09-30 | 2024-03-08 |
| Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) VARIVAX™ - Varicella | Phase 3 | Completed | Merck Sharp & Dohme LLC | 150 | 2019-03-01 | 2021-04-06 |
| An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization Investigational live attenuated varicella vaccine - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 1193 | 2018-07-11 | 2021-12-09 |
| Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II® - Varicella | Phase 3 | Completed | Merck Sharp & Dohme LLC | 600 | 2017-10-17 | 2021-01-27 |
| A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines Investigational live attenuated varicella vaccine, diluent of lyophilized vaccine - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 5997 | 2016-08-01 | 2017-10-26 |
Showing 20 of 64. Sign in to see all of them.
Measles (28) · Mumps (28) · Rubella (28) · Haemophilus Infections (4) · Herpes Zoster (4) · Meningitis, Meningococcal (3) · AIDS-Related Complex (2) · Acquired Immunodeficiency Syndrome (2) · HIV Infections (2) · Communicable Diseases (1) · Diphtheria (1) · Encephalitis, Japanese (1) · Hepatitis A (1) · Hepatitis B (1)
DNA Virus Infections (64) · Infections (64) · Varicella Zoster Virus Infection (64) · Herpesviridae Infections (63) · Virus Diseases (63) · RNA Virus Infections (32) · Mononegavirales Infections (28) · Morbillivirus Infections (28) · Mouth Diseases (28) · Paramyxoviridae Infections (28) · Parotid Diseases (28) · Parotitis (28) · Rubivirus Infections (28) · Rubulavirus Infections (28) · Salivary Gland Diseases (28)
measles, mumps, rubella, varicella vaccine (17) · Chickenpox Vaccine (12) · Measles-Mumps-Rubella Vaccine (10) · Hepatitis A Vaccines (6) · Pneumococcal Vaccines (5) · Herpes Zoster Vaccine (3) · Meningococcal Vaccines (3) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Priorix-Tetra vaccine (2) · Vaccines, Attenuated (2) · 5-propynylarabinofuranosyluracil (1) · Acyclovir (1) · Adenosine Monophosphate (1) · DTPP vaccine (1) · Desipramine (1)
Merck Sharp & Dohme LLC (20) · GlaxoSmithKline (17) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (7) · Sanofi Pasteur, a Sanofi Company (4) · China National Biotec Group Company Limited (2) · SK Bioscience Co., Ltd. (2) · Bristol-Myers Squibb (1) · GC Biopharma Corp (1) · Glaxo Wellcome (1) · National Center for Research Resources (NCRR) (1) · Novartis (1) · Novartis Vaccines (1) · Shanghai Institute Of Biological Products (1) · Suzhou Abogen Biosciences Co., Ltd. (1) · The Hospital for Sick Children (1)
United States (13) · China (7) · Germany (7) · Thailand (5) · Estonia (4) · Italy (4) · Philippines (4) · Poland (4) · Belgium (3) · Czechia (3) · Mexico (3) · Puerto Rico (3) · Brazil (2) · Dominican Republic (2) · Greece (2)
Hongxing Pan (2) · Shengli Xia (2) · Anne Fiquet, MD (1) · Eliane Matos Santos (1) · Glacus S Brito, MD (1) · Klara M Posfay-Barbe, MD, MS (1) · Lili Huang, Bachelor (1) · Nancy Nazaire Bermal, MD (1)
PMID 16452343, PMID 16567978, PMID 16804432, PMID 17502347, PMID 19273678, PMID 19366435, PMID 22123890, PMID 22406278, PMID 22772170, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27423382, PMID 29087781, PMID 29325161, PMID 30481110, PMID 30616012, PMID 30765242, PMID 32429738, PMID 33736915, PMID 34473594, PMID 34702124, PMID 35632416
2025 (2), 2004 (1), 2017 (1), 2019 (1)